Slowed gastric emptying and improved oral glucose tolerance produced by a nanomolar‐potency inhibitor of calcium‐activated chloride channel TMEM16A

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Interstitial cells of Cajal, which express the calcium‐activated chloride channel transmembrane member 16A (TMEM16A), are an important determinant of gastrointestinal (GI) motility. We previously identified the acylaminocycloalkylthiophene class of TMEM16A inhibitors, which, following medicinal chemistry, gave analog 2‐bromodifluoroacetylamino‐5,6,7,8‐tetrahydro‐4 H ‐cyclohepta[ b ]thiophene‐3‐carboxylic acid o ‐tolylamide (TM inh ‐23) with 30 nM half‐maximal inhibitory concentration. Here, we tested the efficacy of TMinh‐23 for inhibition of GI motility in mice. In isolated murine gastric antrum, TM inh ‐23 strongly inhibited spontaneous and carbachol‐stimulated rhythmic contractions. Pharmacokinetic analysis showed predicted therapeutic concentrations of TM inh ‐23 for at least 4 h following a single oral or intraperitoneal dose at 10 mg/kg. Gastric emptying, as assessed following an oral bolus of phenol red or independently by [ 99m Tc]‐diethylenetriamine pentaacetic acid scintigraphy, was reduced by TM inh ‐23 by ∼60% at 20 min. Interestingly, there was little effect of TMinh‐23 on baseline whole‐gut transit time or time to diarrhea induced by castor oil. Consequent to the delay in gastric emptying, TM inh ‐23 administration significantly reduced the elevation in blood sugar in mice following an oral but not intraperitoneal glucose load. These results provide pharmacological evidence for involvement of TMEM16A in gastric emptying and suggest the utility of TMEM16A inhibition in disorders of accelerated gastric emptying, such as dumping syndrome, and potentially for improving glucose tolerance in diabetes mellitus/metabolic syndrome and enhancing satiety in obesity.—Cil, O., Anderson, M. O., Yen, R., Kelleher, B., Huynh, T. L., Seo, Y., Nilsen, S. P., Turner, J. R., Verkman, A. S. Slowed gastric emptying and improved oral glucose tolerance produced by a nanomolar‐potency inhibitor of calcium‐activated chloride channel TMEM16A. FASEB J. 33, 11247–11257 (2019). www.fasebj.org
Funding Information
  • American Heart Association (18POST33990365)
  • Cystic Fibrosis Foundation (VERKMA18G0)
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK72517, DK099803, DK101373)
  • National Eye Institute (EY13574)
  • National Institute of General Medical Sciences (GM102874)

This publication has 46 references indexed in Scilit: